Sept. 23, 2021– The eight pharmaceutical companies that are restricting the discounts they offer through the 340B drug pricing program are blocking safety-net hospitals’ access to savings on a wide range of prescription drugs. But perhaps in no area … [Read More...]
Report by Anti-340B Group Presents Erroneous Picture
Print ArticleSept. 14, 2021– A new report issued by the Community Oncology Alliance (COA) claims 340B hospitals “charge both commercial payers and uninsured patients extraordinarily high prices and use an aggressive form of price discrimination between payers.” However, the report is highly flawed and presents an inaccurate picture of the role 340B plays in America’s health […]
Momentum Grows to End Medicare Cuts for 340B Hospitals
Print ArticleSept. 9, 2021– Calls are increasing for the Biden administration to stop deep Medicare Part B payment cuts to many hospitals participating in the 340B drug pricing program. The reductions, which have been in place since January 2018, have been harmful for many safety-net hospitals and their patients. Earlier this summer, the administration issued […]
FOLLOW | SHARE | LIKE
